These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 31119691)

  • 21. The natural history of progressive fibrosing interstitial lung diseases.
    Kolb M; Vašáková M
    Respir Res; 2019 Mar; 20(1):57. PubMed ID: 30871560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers.
    Faverio P; Piluso M; De Giacomi F; Della Zoppa M; Cassandro R; Harari S; Luppi F; Pesci A
    Respiration; 2020; 99(10):838-845. PubMed ID: 33264777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Use of antifibrotic drugs in interstitial lung disease].
    Kreutz CP; Gesierich W; Behr J; Kneidinger N
    Dtsch Med Wochenschr; 2022 Oct; 147(21):1383-1390. PubMed ID: 36279864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [No Abstract]   [Full Text] [Related]  

  • 25. Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies.
    Li DY; Liu X; Huang JY; Hang WL; Yu GR; Xu Y
    Ther Adv Respir Dis; 2024; 18():17534666241232561. PubMed ID: 38414439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease?
    Soskis A; Hallowell R
    Respiration; 2021; 100(9):923-932. PubMed ID: 33951665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.
    Kim Y; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
    Tohoku J Exp Med; 2018 Nov; 246(3):147-153. PubMed ID: 30405002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute exacerbations of progressive-fibrosing interstitial lung diseases.
    Kolb M; Bondue B; Pesci A; Miyazaki Y; Song JW; Bhatt NY; Huggins JT; Oldham JM; Padilla ML; Roman J; Shapera S
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis.
    Piotrowski WJ; Martusewicz-Boros MM; Białas AJ; Barczyk A; Batko B; Błasińska K; Boros PW; Górska K; Grzanka P; Jassem E; Jastrzębski D; Kaczyńska J; Kowal-Bielecka O; Kucharz E; Kuś J; Kuźnar-Kamińska B; Kwiatkowska B; Langfort R; Lewandowska K; Mackiewicz B; Majewski S; Makowska J; Miłkowska-Dymanowska J; Puścińska E; Siemińska A; Sobiecka M; Soroka-Dąda RA; Szołkowska M; Wiatr E; Ziora D; Śliwiński P
    Adv Respir Med; 2022 Oct; 90(5):425-450. PubMed ID: 36285980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Magnusson MO; Freiwald M
    Respir Med; 2021; 180():106369. PubMed ID: 33798871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Sarr C; Freiwald M
    BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective.
    Albera C; Verri G; Sciarrone F; Sitia E; Mangiapia M; Solidoro P
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
    Hyldgaard C
    Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey.
    Olson A; Hartmann N; Patnaik P; Wallace L; Schlenker-Herceg R; Nasser M; Richeldi L; Hoffmann-Vold AM; Cottin V
    Adv Ther; 2021 Feb; 38(2):854-867. PubMed ID: 33315170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms and management of cough in interstitial lung disease.
    Rasheed AZ; Metersky ML; Ghazal F
    Expert Rev Respir Med; 2023 Dec; 17(12):1177-1190. PubMed ID: 38159067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
    Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
    Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
    Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S; Schlenker-Herceg R; Kolb M;
    Respir Res; 2021 Mar; 22(1):84. PubMed ID: 33726766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and Management of Fibrotic Interstitial Lung Diseases.
    Collins BF; Luppi F
    Clin Chest Med; 2021 Jun; 42(2):321-335. PubMed ID: 34024407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunomodulatory treatment of interstitial lung disease.
    van den Bosch L; Luppi F; Ferrara G; Mura M
    Ther Adv Respir Dis; 2022; 16():17534666221117002. PubMed ID: 35938712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.